Pyxis Oncology, Inc.
PYXS · NASDAQ
12/31/2024 | 12/31/2023 | 12/31/2022 | 12/31/2021 | |
|---|---|---|---|---|
| Market Cap | $0 | $0 | $0 | $0 |
| - Cash | $0 | $0 | $0 | $0 |
| + Debt | $0 | $0 | $0 | $0 |
| Enterprise Value | $0 | $0 | -$0 | $0 |
| Revenue | $0 | $0 | $0 | $0 |
| % Growth | – | – | – | – |
| Gross Profit | $0 | $0 | $0 | $0 |
| % Margin | 97.1% | – | – | – |
| EBITDA | -$0 | -$0 | -$0 | -$0 |
| % Margin | -405.8% | – | – | – |
| Net Income | -$0 | -$0 | -$0 | -$0 |
| % Margin | -478.9% | – | – | – |
| EPS Diluted | -1.32 | -1.85 | -3.57 | -2.53 |
| % Growth | 28.6% | 48.2% | -41.1% | – |
| Operating Cash Flow | -$0 | -$0 | -$0 | -$0 |
| Capital Expenditures | -$0 | -$0 | -$0 | -$0 |
| Free Cash Flow | -$0 | -$0 | -$0 | -$0 |